Literature DB >> 10190275

Matrix-degrading proteases and angiogenesis during development and tumor formation.

Z Werb1, T H Vu, J L Rinkenberger, L M Coussens.   

Abstract

Embryonic development and tumor progression both require the exquisite coordination of programs for extracellular matrix (ECM) formation and remodeling, and those for angiogenesis and vascular development. Without a vascular supply the normal tissue or tumor is limited in size and organization. Without ECM remodeling the alteration of tissue and tumor boundaries and cellular migrations are limited. Recent insights into the molecular mechanisms regulating the extracellular environment of the growing embryonic tissue or tumors have implicated proteases, the matrix metalloproteinases (MMPs) in particular, in both the process of ECM remodeling and angiogenesis, and in a potential causal relationship between these processes. This review focuses on the roles that MMPs play in regulating three processes in which both proteolysis and vascular development are tightly coordinated: embryo implantation, bone development and tumor progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190275     DOI: 10.1111/j.1699-0463.1999.tb01521.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  39 in total

Review 1.  Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules.

Authors:  G E Davis; K J Bayless; M J Davis; G A Meininger
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

Review 2.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

3.  Sustained expression of homeobox D10 inhibits angiogenesis.

Authors:  Connie Myers; Aubri Charboneau; Irene Cheung; Douglas Hanks; Nancy Boudreau
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

4.  Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2.

Authors:  Z Yang; T R Kyriakides; P Bornstein
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

5.  In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds.

Authors:  Gabri van der Pluijm; Martine Deckers; Bianca Sijmons; Henny de Groot; John Bird; Ruth Wills; Socrates Papapoulos; Andy Baxter; Clemens Löwik
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

6.  Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3.

Authors:  Quteba Ebrahem; Jian Hua Qi; Masahiko Sugimoto; Mariya Ali; Jonathan E Sears; Alecia Cutler; Rama Khokha; Amit Vasanji; Bela Anand-Apte
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-03       Impact factor: 4.799

7.  Epidermal development and wound healing in matrix metalloproteinase 13-deficient mice.

Authors:  Bettina Hartenstein; Bernd Thilo Dittrich; Dominique Stickens; Babette Heyer; Thiennu H Vu; Sibylle Teurich; Marina Schorpp-Kistner; Zena Werb; Peter Angel
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

8.  Extracellular matrix fluctuations during early embryogenesis.

Authors:  A Szabó; P A Rupp; B J Rongish; C D Little; A Czirók
Journal:  Phys Biol       Date:  2011-07-12       Impact factor: 2.583

9.  Tumor microenvironment regulates metastasis and metastasis genes of mouse MMTV-PymT mammary cancer cells in vivo.

Authors:  J L Werbeck; N K Thudi; C K Martin; C Premanandan; L Yu; M C Ostrowksi; T J Rosol
Journal:  Vet Pathol       Date:  2013-10-03       Impact factor: 2.221

10.  Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization.

Authors:  Mohammed El Bradey; Lingyun Cheng; Dirk-Uwe Bartsch; Krzystof Appelt; Nuttawut Rodanant; Germaine Bergeron-Lynn; William R Freeman
Journal:  J Ocul Pharmacol Ther       Date:  2004-06       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.